Sanofi – Sanofi and Regeneron’s Dupixent wins EU approval to deal with youngsters
PARIS (Reuters) – Healthcare corporations Sanofi and Regeneron mentioned on Monday that their Dupixent product has received approval from the European Fee to deal with youngsters aged 6-11 affected by extreme atopic dermatitis, typically often known as eczema.
The European Fee had prolonged the advertising approval for Dupixent within the European Union, each corporations mentioned in a joint assertion, citing a trial that confirmed the product resulted in a median enchancment of about 80% within the situation of almost three in 4 youngsters who was affected by extreme atopic dermatitis.
“This approval for Dupixent within the EU represents a significant development for youngsters with extreme atopic dermatitis and their households, who spend numerous days and nights tending to their kid’s illness with few therapy choices to assist alleviate the debilitating signs,” mentioned George D. Yancopoulos, M.D., Ph.D., president and chief scientific officer at Regeneron.
(Reporting by Sudip Kar-Gupta, Enhancing by Sherry Jacob-Phillips)
